NPN Applications in Canada: Why Deficiency Notices Happen — and How to Submit Right the First Time

More than 100,000 natural health products carry a valid NPN in Canada today, each one issued by Health Canada’s Natural and Non-prescription Health Products Directorate (NNHPD). Getting one of those numbers isn’t automatic. A significant proportion of initial product licence applications (PLAs) receive a Deficiency Notice before ever reaching an approval decision — a notice that effectively pauses your review clock and can add six to eighteen months to your timeline.

We’ve worked through dozens of NPN submissions for Canadian clients, from small nutraceutical startups to established pharmaceutical CMOs expanding their NHP portfolios. The deficiency patterns are remarkably consistent. Most aren’t caused by bad science or unsafe products — they’re caused by preventable administrative and documentation gaps that Health Canada’s reviewers flag every time.

Here’s what you need to understand before you submit.

Understanding the NPN Review Pathways

Not all NPN applications go through the same process, and choosing the wrong pathway is itself a common mistake.

Health Canada offers three main submission routes under the Natural Health Products Regulations (SOR/2003-196):

Attestation-based review applies to products whose ingredients and claims appear in Health Canada’s Licensed Natural Health Products Database (LNHPD) or a recognized compendial source. Manufacturers attest that their product meets those published standards. The review target under this pathway is 60 calendar days.

Full evidence review applies to products with novel ingredients, new formulations, or claims not supported by existing licensed product data. This can take up to 210 calendar days under Health Canada’s service standards — and that clock doesn’t start until your application is deemed administratively complete.

Compendial pathway is a subset of the attestation route for products fully described in recognized pharmacopoeias (USP, Ph. Eur., BP). It’s the fastest route when applicable, but the fit needs to be exact.

Choosing the attestation pathway for a product that actually requires a full evidence review is one of the surest ways to trigger a deficiency. Health Canada will identify the mismatch and request additional evidence — which you now need to compile under a response deadline.

The Most Common Deficiency Notice Triggers

Insufficient or Misclassified Evidence

The evidence package is where most submissions fall apart. Under the NHPR, safety and efficacy can be established through three routes: published clinical evidence, traditional use evidence, or references to existing licensed products (for attestation). Each route has specific documentation requirements that reviewers check methodically.

For traditional use claims, evidence must demonstrate that the ingredient has been used within a recognized traditional medicine system for at least 50 years, documented in published references on NNHPD’s accepted list. A single peer-reviewed study from 2021 does not constitute traditional use evidence, no matter how well-designed. We see this confusion frequently with Ayurvedic and Traditional Chinese Medicine ingredients that have genuine historical use but are being supported with modern trial data alone.

For clinical evidence, Health Canada expects studies relevant to your population, your dose, and your proposed indication. Submitting a trial that used a dose 10 times higher than your product without including a pharmacological extrapolation rationale will generate questions.

Incomplete Quantitative Formula

Every medicinal ingredient must be listed with its proper name, quantity per dosage unit, potency where applicable, and source material. For a standardized botanical extract, that means specifying the plant part, extraction ratio, and marker compound. Listing “Ginseng Root Extract 200 mg” without specifying that it’s a 10:1 ratio extract standardized to 4% ginsenosides will produce a deficiency request.

Non-medicinal ingredients matter just as much. You need to list all of them — not only the ones you consider functionally significant — along with their roles (binder, filler, coating agent, preservative). Incomplete non-medicinal lists are a routine flag in the initial administrative screening stage.

Label Deficiencies

Label review is often where reviewers identify the most issues. Health Canada requires specific elements under Schedule 2 of the NHPR, including: product name; dosage form and route of administration; recommended conditions of use (the indication); recommended dose and duration of use; risk information covering cautions, warnings, contraindications, and known adverse reactions; storage conditions; lot number; and expiry date.

Missing duration-of-use language, omitting a contraindication that appears in your own evidence references, or phrasing a health claim differently from how the approved indication is written in your PLA — each of these can stop an application. And all labels sold in Canada must be bilingual. Submitting English-only draft labelling while noting that French translation is “pending” will delay administrative acceptance.

Site Licence Gaps

Your manufacturer and importer must each hold a valid Health Canada Site Licence before your PLA can be approved. This sounds straightforward, but applications stall over it regularly for a few recurring reasons:

• The manufacturing site holds a licence for certain dosage forms (tablets, capsules) but not for the form being submitted (liquids, softgels, transdermal patches)
• The importer’s site licence is mid-renewal and has lapsed
• A contract CMO was added to the supply chain after the original application was submitted, and their licence credentials weren’t updated in the dossier

Health Canada cross-checks site licence status during review. If your contract manufacturer’s licence isn’t current for the relevant activities and dosage forms, your application goes on hold — and the clock doesn’t restart until the licence issue is resolved.

Product Classification Conflicts

Canada draws a meaningful regulatory line between natural health products, foods, and drugs under the Food and Drugs Act (R.S.C., 1985, c. F-27). If your product’s claims or formulation pushes it toward drug territory, the NNHPD can decline to process the NPN application and refer the product to the Pharmaceutical Drugs Directorate.

This most often happens with products claiming to treat, cure, or mitigate a specific disease (versus supporting function or managing a symptom), products containing ingredients at doses typically associated with pharmaceutical use, or combination products with both NHP and drug components. Knowing where your product sits before you submit — and being deliberately conservative with claim language during initial licensing — avoids this outcome entirely.

How to Build a Submission Package That Survives Review

The single most useful step before submitting is running Health Canada’s Product Licence Application checklist against your actual dossier, line by line. It sounds rudimentary, but reviewers consistently flag issues that internal QC would have caught.

Pre-screen your evidence bibliography. If your references are more than five years old, verify they’re still on NNHPD’s accepted references list. Health Canada updates these periodically. A traditional medicine text that was acceptable in 2019 may no longer qualify without supplementary evidence.

Match your label to your submission — exactly. If your PLA lists “Adults: take 2 capsules daily with food” as the recommended dose, that exact language (and its bilingual equivalent) needs to appear on the proposed label. Reviewers compare these verbatim, not by intent.

Confirm site licence status before you click submit. Log into the NNHPD portal and verify active status, licensed activities, and dosage forms for every site in your supply chain. If a renewal is pending, resolve it first. A two-week delay in submission is far less costly than a deficiency-triggered hold.

Use proper names for ingredients, not brand names. The NHPR requires the proper or common name as defined in recognized references. Proprietary ingredient names can be included as supplementary identifiers, but they don’t satisfy the regulatory naming requirement on their own.

Build in time for bilingual label review. Getting French translation reviewed for regulatory accuracy — not just linguistic fluency — takes time and specialized expertise. Factor at least three to four weeks into your pre-submission timeline for complex labels.

What the Timelines Actually Look Like

Even a clean application takes meaningful time. Health Canada’s published service standards are 60 calendar days for the attestation pathway and 210 calendar days for a full evidence review. Those timelines assume an administratively complete application from day one.

A Deficiency Notice pauses the clock, and applicants typically have 90 days to respond. If your response generates a second deficiency — which happens often when the original issue is evidence-based — you can find yourself 18 months or more into a process that should have taken six.

Budget four to six weeks of internal pre-submission review for straightforward formulations. For products going through a full evidence review with non-compendial or novel ingredients, six months of dossier preparation is realistic, not conservative. The companies that move fastest through NNHPD review are the ones that treat the submission package as a regulatory document — drafted deliberately to Health Canada’s framework, not assembled from whatever technical files are already on hand.

That distinction matters more than any single piece of evidence in the dossier.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance. Contact us

Related from our network

• Supplement and NHP Testing for ISO 17025 Compliance — Qalitex Laboratories provides accredited analytical testing for Canadian NHP submissions, including identity, potency, and contaminant profiling to support your NNHPD dossier.
• Understanding EU Cosmetics and Supplement Regulations for Market Entry — Care Europe covers the EU regulatory landscape for manufacturers comparing Health Canada’s NHP framework with EU 1223/2009 and related directives.